Clinical Trials Directory

Trials / Terminated

TerminatedNCT02095717

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Centre Jean Perrin · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant. Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial).

Conditions

Interventions

TypeNameDescription
DRUGCurcumin
DRUGPlacebo
DRUGTaxotere

Timeline

Start date
2014-03-01
Primary completion
2018-04-01
Completion
2018-04-01
First posted
2014-03-26
Last updated
2018-07-24

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02095717. Inclusion in this directory is not an endorsement.

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of P (NCT02095717) · Clinical Trials Directory